Printer Friendly

IMMUNOMEDICS AWARDED PATENT FOR IMAGING AND THERAPEUTIC AGENTS

      IMMUNOMEDICS AWARDED PATENT FOR IMAGING AND THERAPEUTIC AGENTS
    WARREN, N.J., Nov. 4 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU), today announced the issuance of U.S. Patent No. 5,061,641, which broadly covers, in 35 claims, attachment of radioactive metals to antibodies, antibody fragments, and other proteins, such as lymphokines, for imaging and therapeutic applications.  According to one of the inventors, Hans J. Hansen, vice president, exploratory research, "The patent describes direct labeling of protein sulfhydryl groups with a radioactive metal, such as technetium-99m (Tc-99m)."  This isotope is used in all Immunomedics' cancer and infectious disease imaging agents under development and is the preferred isotope in nuclear medicine departments because of its low cost and excellent imaging capabilities.
    "The patent also covers new methods for attaching therapeutic isotopes, such as rhenium-188, to monoclonal antibodies, thus allowing for the development of a new class of therapeutics for cancer and possibly autoimmune diseases," stated Russell C. McLauchlan, Immunomedics' president.  "This new patent and technology should spur the company's imaging and therapy programs and the development of improved monoclonal antibody-based products," McLauchlan further stated.
    Immunomedics has 21 U.S. and 67 foreign issued patents and over 150 patent applications filed worldwide.  A product license application was filed with the U.S. Food and Drug Administration in April 1991, seeking approval to market the company's colorectal cancer imaging agent, a monoclonal antibody fragment labeled with Tc-99m.  The company has a cancer therapeutic involving rhenium-188 completing pre-clinical trials.
    Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases.  Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
    -0-                     11/4/91
    /CONTACT:  Amy Factor of Immunomedics, 908-647-5400/
    (IMMU) CO:  Immunomedics, Inc. ST:  New Jersey IN:  MTC SU: GK-SH -- NY011 -- 0599 11/04/91 09:26 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 4, 1991
Words:327
Previous Article:CHAMPION PARTS REPORTS THIRD-QUARTER PROFITS UP OVER 9 PERCENT ON SLIGHTLY LOWER SALES
Next Article:CARDIS CORP. COMPLETES MILESTONE RECAPITALIZATION
Topics:


Related Articles
IMMUNOMEDICS WINS U.S. PATENT OFFICE APPEAL; BROAD U.S. PATENT ON ORGAN IMAGING ALLOWED
IMMUNOMEDICS ALLOWED PATENT FOR NEW CANCER IMAGING & THERAPY METHODS & AGENTS: FEDERAL GRANT FOR CANCER THERAPEUTIC ALSO AWARDED
IMMUNOMEDICS RECEIVES BROAD EUROPEAN PATENT FOR HIGHLY SPECIFIC CANCER TARGETING ANTIBODIES
IMMUNOMEDICS GRANTED THREE PATENTS IN JAPAN
Immunomedics Awarded U.S. Patent for Therapeutic Conjugates of Toxins and Drugs
Immunomedics Wins Patent in Japan
Immunomedics patents new '2-Punch' therapy of cancer with bispecific fusion proteins.
Immunomedics obtains patent for therapy of B-cell malignancies using antibodies.
Immunomedics obtains lymphoma antibody patent.
Immunomedics granted additional patent.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters